Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.

Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard MC, Prié G, Gouilleux F.

Cancers (Basel). 2020 Jan 18;12(1). pii: E240. doi: 10.3390/cancers12010240. Review.

2.

Direct Targeting Options for STAT3 and STAT5 in Cancer.

Orlova A, Wagner C, de Araujo ED, Bajusz D, Neubauer HA, Herling M, Gunning PT, Keserű GM, Moriggl R.

Cancers (Basel). 2019 Dec 3;11(12). pii: E1930. doi: 10.3390/cancers11121930. Review.

3.

Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.

de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT.

Cancers (Basel). 2019 Nov 8;11(11). pii: E1757. doi: 10.3390/cancers11111757. Review.

4.

Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.

Powell JA, Pitman MR, Zebol JR, Moretti PAB, Neubauer HA, Davies LT, Lewis AC, Dagley LF, Webb AI, Costabile M, Pitson SM.

Biochem J. 2019 Nov 15;476(21):3211-3226. doi: 10.1042/BCJ20190245.

PMID:
31652307
5.

The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis.

Orlova A, Neubauer HA, Moriggl R.

Haematologica. 2019 Oct;104(10):1907-1909. doi: 10.3324/haematol.2019.225862. No abstract available.

6.

STAT3 and STAT5 Activation in Solid Cancers.

Igelmann S, Neubauer HA, Ferbeyre G.

Cancers (Basel). 2019 Sep 25;11(10). pii: E1428. doi: 10.3390/cancers11101428. Review.

7.

Structural and functional consequences of the STAT5BN642H driver mutation.

de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, Seo HS, Qadree AK, Israelian J, Orlova A, Suske T, Pham HTT, Boersma A, Tangermann S, Kenner L, Rülicke T, Dong A, Ravichandran M, Brown PJ, Audette GF, Rauscher S, Dhe-Paganon S, Moriggl R, Gunning PT.

Nat Commun. 2019 Jun 7;10(1):2517. doi: 10.1038/s41467-019-10422-7.

8.

Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival.

Rauth M, Freund P, Orlova A, Grünert S, Tasic N, Han X, Ruan HB, Neubauer HA, Moriggl R.

Int J Mol Sci. 2019 Feb 27;20(5). pii: E1028. doi: 10.3390/ijms20051028. Review.

9.

Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma.

Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM.

Oncogene. 2019 Feb;38(8):1151-1165. doi: 10.1038/s41388-018-0504-9. Epub 2018 Sep 24.

10.

Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Wingelhofer B, Neubauer HA, Valent P, Han X, Constantinescu SN, Gunning PT, Müller M, Moriggl R.

Leukemia. 2018 Aug;32(8):1713-1726. doi: 10.1038/s41375-018-0117-x. Epub 2018 Mar 27. Review.

11.

NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.

Seidi K, Jahanban-Esfahlan R, Monhemi H, Zare P, Minofar B, Daei Farshchi Adli A, Farajzadeh D, Behzadi R, Mesgari Abbasi M, Neubauer HA, Moriggl R, Zarghami N, Javaheri T.

Oncogene. 2018 Jul;37(29):3967-3980. doi: 10.1038/s41388-018-0213-4. Epub 2018 Apr 17.

12.

Tumor target amplification: Implications for nano drug delivery systems.

Seidi K, Neubauer HA, Moriggl R, Jahanban-Esfahlan R, Javaheri T.

J Control Release. 2018 Apr 10;275:142-161. doi: 10.1016/j.jconrel.2018.02.020. Epub 2018 Feb 16. Review.

PMID:
29454742
13.

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Orlova A, Wingelhofer B, Neubauer HA, Maurer B, Berger-Becvar A, Keserű GM, Gunning PT, Valent P, Moriggl R.

Expert Opin Ther Targets. 2018 Jan;22(1):45-57. doi: 10.1080/14728222.2018.1406924. Epub 2017 Nov 24. Review.

14.

CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.

Zhu W, Jarman KE, Lokman NA, Neubauer HA, Davies LT, Gliddon BL, Taing H, Moretti PAB, Oehler MK, Pitman MR, Pitson SM.

Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.

15.

Validation of commercially available sphingosine kinase 2 antibodies for use in immunoblotting, immunoprecipitation and immunofluorescence.

Neubauer HA, Pitson SM.

Version 2. F1000Res. 2016 Dec 6 [revised 2017 Jan 1];5:2825. doi: 10.12688/f1000research.10336.2. eCollection 2016.

16.

An oncogenic role for sphingosine kinase 2.

Neubauer HA, Pham DH, Zebol JR, Moretti PA, Peterson AL, Leclercq TM, Chan H, Powell JA, Pitman MR, Samuel MS, Bonder CS, Creek DJ, Gliddon BL, Pitson SM.

Oncotarget. 2016 Oct 4;7(40):64886-64899. doi: 10.18632/oncotarget.11714.

17.

Roles, regulation and inhibitors of sphingosine kinase 2.

Neubauer HA, Pitson SM.

FEBS J. 2013 Nov;280(21):5317-36. doi: 10.1111/febs.12314. Epub 2013 Jun 7. Review.

Supplemental Content

Loading ...
Support Center